Journal of International Psychiatry

[Abstract] Objective To explore the clinical effect of agomelatine in adjuvant treatment of schizophrenia with obsessive-compulsive symptoms. Methods Eighty-four patients with schizophrenia with obsessive-compulsive symptoms from August 2018 to August 2020 were selected as the study subjects. They were randomly divided into two groups using the digital table method. The control group received conventional quetiapine treatment, and the observation group received adjuvant treatment with agomelatine on the basis of quetiapine for 8 consecutive weeks. The yale-brown obsessive-compulsive scale (Y-BCOS), social function deficiency screening scale (SDSS), and positive and negative symptom scale (PANSS) were compared between the two groups before and after treatment. The incidence of adverse reactions between the two groups were compared. Results The Y-BCOS score and SDSS score of the two groups decreased significantly after treatment, but the observation group was significantly lower than the control group after treatment (P<0.05). The psychopathological symptoms, positive symptom scores, and negative symptom scores in the PANSS scale of the two groups were significantly reduced after treatment, but the observation group was significantly lower than the control group after treatment (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Agomelatine adjuvant treatment of schizophrenia with obsessive-compulsive symptoms can reduce obsessive-compulsive symptoms, improve social function, and help relieve the positive, negative and mental symptoms of schizophrenia. It is safe and effective in clinical application.

Key words Agomelatine; Quetiapine; Obsessive-Compulsive Symptoms; Schizophrenia